Abstract
The blood-brain barrier (BBB) protects the brain against endogenous and exogenous compounds and plays an important part in the maintenance of the microenvironment of the brain. In particular, the importance of brain-to-blood transport of brain-derived metabolites across the BBB has gained increasing attention as a potential mechanism in the pathogenesis of neurodegenerative disorders such as Alzheimers disease, which is characterized by the aberrant polymerization and accumulation of specific misfolded proteins, particularly β-amyloid (Aβ). There is growing evidence that the ABC transport protein P-glycoprotein (P-gp), a major component of the BBB, mediates the efflux of Aβ from the brain. In this review, we discuss the possible role of P-gp in Alzheimers disease and other neurodegenerative disorders, and consider how a fuller understanding of this function might promote the development of more effective treatment strategies.
Keywords: β-amyloid, P-glycoprotein, Alzheimer's disease, neurodegeneration, blood-brain barrier, Creutzfeldt-Jakob disease, aging, autopsy, immunotherapy, Microglia
Current Pharmaceutical Design
Title: The Role of the ATP-Binding Cassette Transporter P-Glycoprotein in the Transport of β-Amyloid Across the Blood-Brain Barrier
Volume: 17 Issue: 26
Author(s): Silke Vogelgesang, Gabriele Jedlitschky, Anja Brenn and Lary C. Walker
Affiliation:
Keywords: β-amyloid, P-glycoprotein, Alzheimer's disease, neurodegeneration, blood-brain barrier, Creutzfeldt-Jakob disease, aging, autopsy, immunotherapy, Microglia
Abstract: The blood-brain barrier (BBB) protects the brain against endogenous and exogenous compounds and plays an important part in the maintenance of the microenvironment of the brain. In particular, the importance of brain-to-blood transport of brain-derived metabolites across the BBB has gained increasing attention as a potential mechanism in the pathogenesis of neurodegenerative disorders such as Alzheimers disease, which is characterized by the aberrant polymerization and accumulation of specific misfolded proteins, particularly β-amyloid (Aβ). There is growing evidence that the ABC transport protein P-glycoprotein (P-gp), a major component of the BBB, mediates the efflux of Aβ from the brain. In this review, we discuss the possible role of P-gp in Alzheimers disease and other neurodegenerative disorders, and consider how a fuller understanding of this function might promote the development of more effective treatment strategies.
Export Options
About this article
Cite this article as:
Vogelgesang Silke, Jedlitschky Gabriele, Brenn Anja and C. Walker Lary, The Role of the ATP-Binding Cassette Transporter P-Glycoprotein in the Transport of β-Amyloid Across the Blood-Brain Barrier, Current Pharmaceutical Design 2011; 17(26) . https://dx.doi.org/10.2174/138161211797440168
DOI https://dx.doi.org/10.2174/138161211797440168 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Alzheimer’s Disease Amyloid Peptides Interact with DNA, As Proved by Surface Plasmon Resonance
Current Alzheimer Research Erythropoietin Requires NF-κB and its Nuclear Translocation to Prevent Early and Late Apoptotic Neuronal Injury During β-Amyloid Toxicity
Current Neurovascular Research Type 2 Diabetes Mellitus: New Genetic Insights will Lead to New Therapeutics
Current Genomics From Preclinical to Clinical Trials: An Update on Potential Therapies for Huntington’s Disease
Current Psychopharmacology Metabolic Profiling in Multiple Sclerosis and Other Disorders by Quantitative Analysis of Cerebrospinal Fluid Using Nuclear Magnetic Resonance Spectroscopy
Current Pharmaceutical Biotechnology Ages of Onset of Mood and Anxiety Disorders in Fragile X Premutation Carriers
Current Psychiatry Reviews Increased Acetylation of Histone H4 at Lysine 12 (H4K12) in Monocytes of Transgenic Alzheimer’s Mice and in Human Patients
Current Alzheimer Research Neuroprotective Effect of Resveratrol Against Methamphetamine-Induced Dopaminergic Apoptotic Cell Death in a Cell Culture Model of Neurotoxicity
Current Neuropharmacology Commentary (Brilliant Blue G: What a Little More Colour Can Be)
CNS & Neurological Disorders - Drug Targets Biphasic Mechanisms of Neurovascular Unit Injury and Protection in CNS Diseases
CNS & Neurological Disorders - Drug Targets Tau in Alzheimer Disease and Related Tauopathies
Current Alzheimer Research Selenium in the Therapy of Neurological Diseases. Where is it Going?
Current Neuropharmacology Prediction of Gene Co-Expression by Quantifying Heterogeneous Features
Current Bioinformatics Investigational Selective Melatoninergic Ligands for Receptor Subtype MT2
Mini-Reviews in Medicinal Chemistry Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences Adrenergic Drugs Blockers or Enhancers for Cognitive Decline ? What to Choose for Alzheimer’s Disease Patients?
CNS & Neurological Disorders - Drug Targets Metformin: Repurposing Opportunities for Cognitive and Mood Dysfunction
CNS & Neurological Disorders - Drug Targets The Role of Glucose in the Pathogenesis of Alzheimers Disease Revisited:What Does it Tell us About the Therapeutic use of Lithium?
Central Nervous System Agents in Medicinal Chemistry RNA Metabolism in Neurodegenerative Disease
Current Chemical Biology Quercetin in Attenuation of Ischemic/Reperfusion Injury: A Review
Current Molecular Pharmacology